Western companies drive Chinese biotech licensing deal blitz
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers that have insufficient capital to fund late-stage drug development and global expansion. Merck, GSK and AstraZeneca have all signed …